Categories: News

eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference at 2:40 p.m. ET on Tuesday, September 28, 2021. eFFECTOR will also host investor meetings throughout the conference.

A live webcast of the fireside chat will be available on the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.effector.com.

About eFFECTOR Therapeutics

eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of multiple functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. In addition to the company’s oncology focus, zotatifin is being evaluated as a potential host-directed anti-viral therapy in patients with mild to moderate COVID-19 in collaboration with the University of California, San Francisco, under a $5 million grant sponsored by the Defense Advanced Research Projects Agency.

Contacts:

Investors:
Stephanie Carrington
Westwicke, an ICR Company
646-277-1282
Stephanie.Carrington@westwicke.com

Media:
Heidi Chokeir, Ph.D.
Canale Communications
619-203-5391
heidi.chokeir@canalecomm.com

Staff

Recent Posts

Quantum BioPharma Announces Update to Previously Announced Private Placement

Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)…

55 minutes ago

MyndTec Inc. Announces Planned Chief Financial Officer Transition

Mississauga, Ontario--(Newsfile Corp. - August 11, 2025) -  MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a…

2 hours ago

Chadwick S. Richard, M.D. Now Offering patients the Hybrid Choice™ Concierge Program from Concierge Choice Physicians

Chadwick S. Richard, M.D., an Internal medicine physician from Medical Clinic of Houston, gives patients the…

2 hours ago

tendercare Launches on Android, Helping Millions More Families Collaborate with Family Caregiving Tools

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- tendercare, the free, easy-to-use, and collaborative technology platform transforming…

2 hours ago

Garden Launches BLOOM to Make AI Drug Design IP-Aware in Real Time

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Garden today announced BLOOM (Branching Lookup Optimized for…

2 hours ago

Top Los Angeles Oral and Maxillofacial Surgeon Dr. David Salehani Enhances Genioplasty and Corrective Jaw Surgery with Virtual Surgical Planning

Dr. David Salehani, a top Los Angeles oral and maxillofacial surgeon, is revolutionizing chin and jaw…

2 hours ago